Because of the considerable impact of cancers and inflammatory processes on mortality and morbidity rates worldwide, it is imperative to continue to find new therapeutic pathways by seeking, directly or indirectly, to inhibit the canonical system WN/β-catenin and to activate PPARγ by new agonists free of deleterious effects. This evidence concerns the gene PPARG and cancer.